Matsuo S, Watanabe J, Mitsuya K, Hayashi N, Nakasu Y, Hayashi M. Brain metastasis in patients with metastatic breast cancer in the real world: a single-institution, retrospective review of 12-year follow-up. Breast Cancer Res Treat. 2017;162:169–79. https://doi.org/10.1007/s10549-017-4107-x.

Article  CAS  PubMed  Google Scholar 

Soffietti R, Abacioglu U, Baumert B, Combs SE, Kinhult S, Kros JM, et al. Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO). Neuro Oncol. 2017;19:162–74. https://doi.org/10.1093/neuonc/now241.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Weil RJ, Palmieri DC, Bronder JL, Stark AM, Steeg PS. Breast cancer metastasis to the central nervous system. Am J Pathol. 2005;167:913–20. https://doi.org/10.1016/s0002-9440(10)61180-7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Farahani MK, Gharibshahian M, Rezvani A, Vaez A. Breast cancer brain metastasis: from etiology to state-of-the-art modeling. J Biol Eng. 2023;17:41. https://doi.org/10.1186/s13036-023-00352-w.

Article  PubMed  PubMed Central  Google Scholar 

Kim M, Kizilbash SH, Laramy JK, Gampa G, Parrish KE, Sarkaria JN, et al. Barriers to effective drug treatment for brain metastases: a multifactorial problem in the delivery of precision medicine. Pharm Res. 2018;35:177. https://doi.org/10.1007/s11095-018-2455-9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Drago JZ, Modi S, Chandarlapaty S. Unlocking the potential of antibody-drug conjugates for cancer therapy. Nat Rev Clin Oncol. 2021;18:327–44. https://doi.org/10.1038/s41571-021-00470-8.

Article  PubMed  PubMed Central  Google Scholar 

Bartsch R, Berghoff AS, Furtner J, Marhold M, Bergen ES, Roider-Schur S, et al. Trastuzumab Deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial. Nat Med. 2022;28:1840–7. https://doi.org/10.1038/s41591-022-01935-8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pérez-García JM, Vaz Batista M, Cortez P, Ruiz-Borrego M, Cejalvo JM, de la Haba-Rodriguez J, et al. Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: the DEBBRAH trial. Neuro Oncol. 2023;25:157–66. https://doi.org/10.1093/neuonc/noac144.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kabraji S, Ni J, Sammons S, Li T, Van Swearingen AED, Wang Y, et al. Preclinical and clinical efficacy of Trastuzumab Deruxtecan in breast cancer brain metastases. Clin Cancer Res. 2023;29:174–82. https://doi.org/10.1158/1078-0432.Ccr-22-1138.

Article  CAS  PubMed  PubMed Central  Google Scholar 

André F, Cortés J, Curigliano G, Modi S, Li W, Park YH, et al. A pooled analysis of Trastuzumab Deruxtecan in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer with brain metastases. Ann Oncol. 2024;35:1169–80. https://doi.org/10.1016/j.annonc.2024.08.2347.

Article  CAS  PubMed  Google Scholar 

Harbeck N, Ciruelos E, Jerusalem G, Müller V, Niikura N, Viale G, et al. Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial. Nat Med. 2024;30:3717–27. https://doi.org/10.1038/s41591-024-03261-7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, et al. Trastuzumab Deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022;387:9–20. https://doi.org/10.1056/NEJMoa2203690.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lenárt S, Lenárt P, Šmarda J, Remšík J, Souček K, Beneš P. Trop2: jack of all trades, master of none. Cancers (Basel). 2020. https://doi.org/10.3390/cancers12113328.

Article  PubMed  PubMed Central  Google Scholar 

Krop IE, Masuda N, Mukohara T, Takahashi S, Nakayama T, Inoue K, et al. Patritumab Deruxtecan (HER3-DXd), a human epidermal growth factor receptor 3-directed antibody-drug conjugate, in patients with previously treated human epidermal growth factor receptor 3-expressing metastatic breast cancer: a multicenter, phase I/II trial. J Clin Oncol. 2023;41:5550–60. https://doi.org/10.1200/jco.23.00882.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lipinski M, Parks DR, Rouse RV, Herzenberg LA. Human trophoblast cell-surface antigens defined by monoclonal antibodies. Proc Natl Acad Sci USA. 1981;78:5147–50. https://doi.org/10.1073/pnas.78.8.5147.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rader RK, Anders CK, Lin NU, Sammons SL. Available systemic treatments and emerging therapies for breast cancer brain metastases. Curr Treat Options Oncol. 2023;24:611–27. https://doi.org/10.1007/s11864-023-01086-z.

Article  PubMed  Google Scholar 

Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, et al. Sacituzumab Govitecan in metastatic triple-negative breast cancer. N Engl J Med. 2021;384:1529–41. https://doi.org/10.1056/NEJMoa2028485.

Article  CAS  PubMed  Google Scholar 

Rugo HS, Bardia A, Marmé F, Cortés J, Schmid P, Loirat D, et al. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2023;402:1423–33. https://doi.org/10.1016/s0140-6736(23)01245-x.

Article  CAS  PubMed  Google Scholar 

Hurvitz SA, Bardia A, Punie K, Kalinsky K, Carey LA, Rugo HS, et al. Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer. NPJ Breast Cancer. 2024;10:33. https://doi.org/10.1038/s41523-024-00635-5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Naidu R, Yadav M, Nair S, Kutty MK. Expression of c-erbB3 protein in primary breast carcinomas. Br J Cancer. 1998;78:1385–90. https://doi.org/10.1038/bjc.1998.689.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ocana A, Vera-Badillo F, Seruga B, Templeton A, Pandiella A, Amir E. HER3 overexpression and survival in solid tumors: A meta-analysis. J Natl Cancer Inst. 2013;105:266–73. https://doi.org/10.1093/jnci/djs501.

Article  CAS  PubMed  Google Scholar 

Travis A, Pinder SE, Robertson JF, Bell JA, Wencyk P, Gullick WJ, et al. C-erbB-3 in human breast carcinoma: expression and relation to prognosis and established prognostic indicators. Br J Cancer. 1996;74:229–33. https://doi.org/10.1038/bjc.1996.342.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Witton CJ, Reeves JR, Going JJ, Cooke TG, Bartlett JM. Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol. 2003;200:290–7. https://doi.org/10.1002/path.1370.

Article  CAS  PubMed  Google Scholar 

Pistilli B, Pierotti L, Lacroix-Triki M, Vicier C, Frenel JS, D’Hondt V, et al. 340O Efficacy, safety and biomarker analysis of ICARUS-BREAST01: a phase II study of Patritumab deruxtecan (HER3-DXd) in patients (pts) with HR+/HER2- advanced breast cancer (ABC). Ann Oncol. 2024. https://doi.org/10.1016/j.annonc.2024.08.288.

Article  PubMed  Google Scholar 

Yu HA, Goto Y, Hayashi H, Felip E, Chih-Hsin Yang J, Reck M, et al. HERTHENA-Lung01, a phase II trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-mutated non-small-cell lung cancer after Epidermal Growth Factor Receptor tyrosine kinase inhibitor therapy and platinum-based chemotherapy. J Clin Oncol. 2023;41:5363–75. https://doi.org/10.1200/jco.23.01476.

Article  CAS  PubMed  PubMed Central  Google Scholar